Back to top
more

Seattle Genetics, Inc. (SGEN)

(Delayed Data from NSDQ)

$67.25 USD

67.25
574,388

+0.33 (0.49%)

Updated May 3, 2019 04:00 PM ET

After-Market: $67.27 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks News

The Zacks Analyst Blog Highlights: Merck, Celgene, Gilead Sciences, Seattle Genetics and Vanda Pharmaceuticals

The Zacks Analyst Blog Highlights: Merck, Celgene, Gilead Sciences, Seattle Genetics and Vanda Pharmaceuticals

    5 Drug Stocks Well Poised to Beat Q2 Earnings Estimates

    The NYSE ARCA Pharmaceutical Index has risen almost 9.8% year to date.

      Pfizer's Mylotarg Recommended by FDA Advisory Committee

      Pfizer Inc. (PFE) announced that the FDA's Oncologic Drug Advisory Committee (ODAC) voted in favor of Mylotarg for the treatment of patients with newly-diagnosed CD33-positive acute myeloid leukemia (AML).

        Bristol-Myers' Opdivo Superior to Yervoy in Melanoma Study

        Bristol-Myers Squibb Company (BMY) announced that a phase III study, CheckMate-238, evaluating Opdivo 3 mg/kg versus Yervoy 10 mg/kg met its primary endpoint at a planned interim analysis.

          Roche's (RHHBY) Leukemia Drug Gets Prime Status in EU

          Roche (RHHBY) announced that its investigational drug polatuzumab vedot in combination with MabThera and bendamustine was granted prime status in the EU.

            Seattle Genetics (SGEN) Reports Positive Data for Adcetris

            Seattle Genetics, Inc. (SGEN) and partner Takeda Pharmaceutical Company Limited announced positive results from phase III study, ECHLEON 1 study.

              Seattle Genetics (SGEN) Submits BLA to FDA for Cancer Drug

              Seattle Genetics, Inc. (SGEN) announced that it has submitted a supplemental Biologics License Application (sBLA) to the FDA for Adcetris (brentuximab vedotin) in patients with cutaneous T-cell lymphoma (CTCL).

                Seattle Genetics Halts Phase III Study on Leukemia Drug

                Seattle Genetics, Inc. (SGEN) announced that it will discontinue the phase III study, CASCADE o vadastuximab talirine (SGN-CD33A) in frontline older acute myeloid leukemia (AML) patients.

                  Bristol-Myers Opdivo Positive in Phase II Study CheckMate-205

                  Bristol-Myers Squibb Company (BMY) announced an extended follow-up data on immuno-oncology drug Opdivo.

                    Seattle Genetics Reports Updated Results on Cancer Drug

                    Seattle Genetics, Inc. (SGEN) and Astellas announced positive phase I results for pipeline candidate enfortumab vedotin (ASG-22ME).

                      Bristol-Myers Presents Data on Immuno-Oncology Drug Opdivo

                      Bristol-Myers BMY announced that the EC has approved immuno-oncology drug Opdivo for the treatment of locally advanced unresectable or metastatic urothelial carcinoma (mUC) in adults after failure of prior platinum-containing therapy.

                        Seattle Genetics (SGEN) Q1 Loss Widens, Sales Top Estimates

                        Seattle Genetics, Inc. (SGEN) reported a loss of 42 cents per share for the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 41 cents and the year-ago loss of 15 cents per share.

                          New Strong Sell Stocks for April 3rd

                          Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

                            Seattle Genetics (SGEN) Up 8.2% Since Earnings Report: Can It Continue?

                            Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                              Joseph Lu headshot

                              Immunomedics (IMMU) Stock Soars After Deal with Seattle Genetics Is Halted

                              Immunomedics, Inc. (IMMU) stock soared in midday trading Thursday following the stop on the company's deal with Seattle Genetics (SGEN) after the lawsuit filed by Immunomedics' largest investor, venBio Select Advisor LLC, reported by The Street.

                                Seattle Genetics (SGEN): FDA Lifts Hold on Trial of AML Drug

                                Seattle Genetics, Inc. (SGEN) announced that the FDA has lifted the clinical hold on two phase I trials of its candidate, vadastuximab talirine (SGN-CD33A; 33A).

                                  Arch Coal, Seattle Genetics, Skyworks Solutions, Texas Instruments and Apple highlighted as Zacks Bull and Bear of the Day

                                  Arch Coal, Seattle Genetics, Skyworks Solutions, Texas Instruments and Apple highlighted as Zacks Bull and Bear of the Day

                                    Brian Hamilton headshot

                                    Bear of the Day: Seattle Genetics (SGEN)

                                    Seattle Genetics recently reported both a top and bottom line miss, and reduced 2017 sales expectations.

                                      Seattle Genetics (SGEN) Loss Wider than Expected in Q4, Revenues Miss

                                      Seattle Genetics, Inc (SGEN) reported a loss of 39 cents per share, wider than the Zacks Consensus Estimate of a loss of 34 cents and wider than the year-ago loss of 18 cents.

                                        Seattle Genetics' Acute Myeloid Leukemia Drug on FDA Hold

                                        Seattle (SGEN) announced that the FDA had placed a clinical hold or partial clinical hold on several early-stage studies on SGN-CD33A for the treatment of AML.

                                          Arpita Dutt headshot

                                          Biotech Stock Roundup: FDA Nod for Biogen/Ionis Drug, Seattle Genetics Hit by Clinical Hold

                                          Biogen (BIIB) and Ionis got an early Christmas gift with the FDA approving their spinal muscular atrophy drug within three months of regulatory filing.

                                            Bristol-Myers Reports Data from Opdivo Combination Studies

                                            Bristol-Myers (BMY) presented multiple data from Opdivo combination studies.

                                              5 Biotech Stocks to Bet on This Earnings Season

                                              The happening biotech sector should be a good bet for investors.